NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading AQST? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and operates in a volatile management environment, which adds uncertainty to its long-term prospects.
The market appears to have a low expectations gap, suggesting that current valuations reflect some level of fragility. AQST is priced at a premium compared to its peers, indicating that investors may be factoring in potential future growth despite the company's current losses.
Management has set ambitious revenue targets for 2026, with recent performance showing progress toward these goals. However, the company remains loss-making, and its ability to manage these losses will be crucial in the near term.
The long-term thesis hinges on the company's ability to resubmit its Anaphylm NDA successfully and achieve its revenue targets. Additionally, the performance of sector bellwethers will significantly influence AQST's trajectory, as positive trends in the healthcare sector could provide support.
Overall, AQST is in a watch state, with mixed signals on its execution and external factors impacting its prospects. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting revenue targets shows the company is on track for its $46-$50M goal for 2026.
Confirms:Q2 2026 revenue reported at or above $14.45M.
Disproves:Q2 2026 revenue reported below $14.45M.
Why it matters: Earnings will provide insights into revenue growth and cost management.
Confirms one read:Earnings report shows revenue growth and improved EBITDA loss.
Confirms the other:The earnings report shows lower revenue. It also shows a bigger EBITDA loss.
Why it matters: The resubmission is key for Anaphylm's approval. It could lead to significant revenue if approved.
Confirms:The company officially submits the Anaphylm NDA by the end of Q3 2026.
Disproves:The company will delay the Anaphylm NDA resubmission. It will happen after Q3 2026.
Why it matters: Managing EBITDA loss is key for financial health. It reflects cost control efforts.
Confirms:EBITDA loss reported within the range of $30-$35M for 2026.
Disproves:The EBITDA loss for 2026 is over $35M.
Why it matters: Good results could show that AQST-108 may help treat skin conditions.
Confirms:The company releases positive data from the AQST-108 phase 1 study.
Disproves:The company reports safety problems or bad results from the AQST-108 phase 1 study.
Why it matters: Hitting this target shows the company is on track for growth and financial health.
Confirms:The company reports total revenue of $46 million or more for 2026.
Disproves:The company reports total revenue below $46 million for 2026.
Why it matters: Good feedback from the FDA could speed up Anaphylm's approval process.
Confirms:The FDA gives good feedback on the Anaphylm resubmission request.
Disproves:The FDA issues further concerns or delays the review process for Anaphylm.
